A real-world study found no significant improvement in breast cancer detection or recall rates with an FDA-approved AI mammography tool in a single-reader setting.
Key Details
- 1Study reviewed 24,520 screening mammograms post-AI and 21,630 pre-AI, all using digital breast tomosynthesis (DBT).
- 2Recall rate was 12.3% before and 12.8% after AI implementation (p=0.13).
- 3Cancer detection rate per 1,000 women was 6.7 pre-AI and 7 post-AI (p=0.69), indicating no significant difference.
- 4AI categorized 61.3% as low risk, 34.9% as intermediate, and 3.8% as elevated risk, with cancer detection rates in those groups at 0.5, 8.4, and 98 per 1,000, respectively (p<0.001).
- 5AI missed 15 out of 171 diagnosed cancers, mostly among low- and intermediate-risk cases not flagged by AI.
- 6Authors suggest AI may aid in patient risk stratification, but primary screening metrics did not improve.
Why It Matters
While prior European studies in double-reading environments showed AI could improve detection or reduce workload, this large U.S. study indicates no significant breast cancer screening benefit in single-reader practice. The findings highlight the need for more nuanced evaluation of AI tools in real-world clinical workflows and may guide future U.S. AI adoption and regulatory considerations.
Source
AuntMinnie
Related News
•AuntMinnie
AI in Radiology: Augmentation, Not Replacement – Risks and Realities Reviewed
AI is reshaping radiology workflows but is not ready to replace radiologists, as judgment, accountability, and clinical complexity remain unmet by current technology.
•AuntMinnie
AI-Driven Mammogram Analysis Boosts Cardiovascular Risk Prediction in Women
AI quantification of breast arterial calcifications (BACs) on mammograms enhances prediction of cardiovascular events beyond traditional risk models.
•AuntMinnie
AI-CAD Boosts Specificity and Efficiency in Asia-Pacific Mammography Study
AI-CAD systems increased specificity and cut interpretation times in a multicenter Asia-Pacific mammography study.